Scarica l'app Stockscreener
1.20
0.41%
-0.005
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.205
Aprire:
$1.2
Volume 24 ore:
44,905
Relative Volume:
0.58
Capitalizzazione di mercato:
$12.74M
Reddito:
$3,000
Utile/perdita netta:
$-8.54M
Rapporto P/E:
-0.6956
EPS:
-1.7252
Flusso di cassa netto:
$-7.51M
1 W Prestazione:
-2.44%
1M Prestazione:
-3.23%
6M Prestazione:
-14.89%
1 anno Prestazione:
-54.37%
Intervallo 1D:
$1.15
$1.2599
Intervallo di 1 settimana:
$1.1201
$1.28
Portata 52W:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
5.30 | 490.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
7.42 | 364.76M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
19.92 | 372.90M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
43.93 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.50 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
BioCardia (BCDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit - MSN
BioCardia, Inc. Reports 2026 Financial Results and CardiAMP Clinical Program Updates - Minichart
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... By GuruFocus - Investing.com Canada
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
BioCardia (BCDA) Highlights Clinical Progress and Financials in Q4 2025 - GuruFocus
BioCardia, Inc.: Advancing Cell Therapy Systems for Heart Failure and Cardiovascular Disease – Clinical Trials, FDA Approvals, and Business Strategies (2025) - Minichart
BioCardia, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCDA) 2026-03-24 - Seeking Alpha
Biocardia Inc's HF2 Trial Enrollment and Regulatory Timeline Claims Clash in 2025 Earnings Calls - Bitget
BCDA: Phase III CardiAMP HF data support regulatory filings as financials remain stable and catalysts approach - TradingView
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress - Investing.com Canada
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCDA: CardiAMP therapy advances toward regulatory approval with strong clinical data and stable finances - TradingView
BIOCARDIA ($BCDA) Releases Q4 2025 Earnings - Quiver Quantitative
BCDA: Positive clinical trial results and regulatory progress, but net loss widened to $8.2 million - TradingView
[10-K] BioCardia, Inc. Files Annua... - Stock Titan
BioCardia Reports 2025 Business Highlights and Financial Results - marketscreener.com
BioCardia Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BioCardia, Inc. to Host Conference Call for 2025 Financial Results and Corporate Update on March 24, 2026 - Quiver Quantitative
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - GlobeNewswire
BioCardia to give corporate update with 2025 results on March 24 - Stock Titan
Quarterly Risk: Does BioCardia Inc stock have upside surprise potential2026 Technical Overview & Expert Approved Trade Ideas - baoquankhu1.vn
FDA accepts BioCardia pre-submission for Helix catheter By Investing.com - Investing.com South Africa
BioCardia Inc Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA - marketscreener.com
BioCardia Announces FDA Review of Helix Transendocardial Delivery Catheter Pre-Submission Package – Key 2026 Regulatory Milestones - Minichart
FDA accepts BioCardia pre-submission for Helix catheter - Investing.com
BioCardia (BCDA) Advances Heart Catheter Approval with FDA Submi - GuruFocus
BioCardia Advances Helix Catheter Toward FDA Marketing Clearance - TipRanks
BioCardia Announces Pre-Submission Approval Package For Helix Transendocardial Delivery Catheter Accepted By FDA - TradingView
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA - The Manila Times
BioCardia® Announces FDA Acceptance of Pre-Submission Package for Helix Transendocardial Delivery Catheter - Quiver Quantitative
FDA accepts BioCardia (NASDAQ: BCDA) Helix catheter pre-submission for review - Stock Titan
BioCardia Announces Pre-Submission Approval Package for - GlobeNewswire
Chart Watch: Is now the right time to enter BioCardia IncDay Trade & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
BCDA Stock Price, Quote & Chart | BIOCARDIA INC (NASDAQ:BCDA) - ChartMill
Aug Reactions: Can BioCardia Inc ride the EV wave2026 Performance Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Weekly Recap: Is BioCardia Inc a momentum stock2026 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
BioCardia files prospectus for resale of 549K shares; stock down 8.6% - MSN
Market Outlook: Whats the profit margin of BioCardia IncJuly 2025 EndofMonth & Weekly Top Stock Performers List - baoquankhu1.vn
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) - Bitget
BioCardia Highlights Positive CardiAMP Phase III Heart Failure Data - TipRanks
BioCardia reports positive echocardiography results from Phase III CardiAMP HF trial indicating reduced ventricular remodeling - TradingView
New CardiAMP HF echo data from BioCardia (NASDAQ: BCDA) highlight ventricular remodeling - Stock Titan
Heart failure cell therapy shows less adverse cardiac remodeling - Stock Titan
BCDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BCDA Should I Buy - Intellectia AI
Loss Report: Can BioCardia Inc ride the EV wavePortfolio Profit Report & Daily Growth Stock Tips - baoquankhu1.vn
BioCardia (NASDAQ:BCDA) Trading Up 3.1% – Here’s Why - Defense World
Chipmakers Recap: Does BioCardia Inc have pricing powerQuarterly Performance Summary & Fast Gaining Stock Reports - baoquankhu1.vn
S P Trends: Can BioCardia Inc. ride the EV waveMarket Trend Review & Verified Short-Term Plans - mfd.ru
BCDA PE Ratio & Valuation, Is BCDA Overvalued - Intellectia AI
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):